In short
This article explores the ongoing clinical trials of Cabotegravir Sodium, a potential long-acting treatment for HIV infections. The study aims to assess the safety, tolerability, and effectiveness of different formulations and administration methods of Cabotegravir, providing valuable insights into its potential as a new option for HIV management.
At a glance
- Study Type
- Phase 1, double-blind, active-control, randomized study
- Drug Studied
- Cabotegravir Sodium (CAB)
- Formulations
- Oral tablets (30 mg), Injectable solutions (200 mg/mL and 400 mg/mL)
- Administration Methods
- Oral, Intramuscular (IM) injection, Subcutaneous (SC) injection
- Injection Sites
- Gluteus medius (buttocks), Vastus lateralis (thigh), Abdominal area
- Dosing Schedules
- Every 4 weeks (Q4W) in Part 1, Every 12 weeks (Q12W) in Part 2
- Primary Outcomes
- Pharmacokinetic parameters (Cmax, Tmax, AUC, Ctau, T1/2, KALA)
- Secondary Outcomes
- Safety assessments, Adverse events, Liver function tests
- Study Duration
- Up to 52 weeks follow-up
What is Cabotegravir?
Cabotegravir sodium, also known as CAB, is a medication being studied for the treatment of HIV infections. HIV, or Human Immunodeficiency Virus, is a virus that attacks the body's immune system, making it difficult to fight off infections and diseases. Cabotegravir belongs to a class of drugs called integrase inhibitors, which work by preventing the HIV virus from multiplying in the body.
How is Cabotegravir Administered?
Cabotegravir can be administered in several ways:
- Oral tablets: 30 mg tablets for oral administration, typically used as a lead-in treatment.
- Intramuscular (IM) injection: Injected into the muscle, usually in the buttocks (gluteus medius) or thigh (vastus lateralis).
- Subcutaneous (SC) injection: Injected under the skin, typically in the abdominal area.
The study is testing two different concentrations of cabotegravir for injections:
- Cabotegravir 400 mg/mL: A higher concentration formulation
- Cabotegravir 200 mg/mL: A lower concentration formulation used as an active comparator
Clinical Trial Overview
The clinical trial (NCT04484337) is designed to evaluate the pharmacokinetics, safety, and tolerability of cabotegravir. Pharmacokinetics refers to how the drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted. This information helps researchers understand how the medication behaves in the body and determine the most effective dosing regimen.
Study Design
The study is divided into two parts:
- Part 1: Participants receive repeat doses of cabotegravir at four-week (Q4W) intervals.
- Part 2: Participants receive repeat doses of cabotegravir at twelve-week (Q12W) intervals.
The study is designed as a double-blind trial, meaning that neither the participants nor the immediate study team knows which specific treatment each participant is receiving. This helps to prevent bias in the study results.
Outcomes Measured
The study measures several key aspects of how cabotegravir behaves in the body:
- Maximum concentration (Cmax): The highest level of the drug in the blood after administration.
- Time to maximum concentration (Tmax): How long it takes to reach the highest drug level in the blood.
- Area under the curve (AUC): A measure of the total exposure to the drug over time.
- Trough concentration (Ctau): The lowest level of the drug in the blood just before the next dose.
- Half-life (T1/2): The time it takes for half of the drug to be eliminated from the body.
- Absorption rate (KALA): How quickly the drug is absorbed into the bloodstream.
These measurements help researchers understand how long the drug stays in the body and how often it needs to be administered to maintain effective levels.
Safety Considerations
The study also focuses on the safety of cabotegravir by monitoring:
- Adverse events (AEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the study, whether or not it's related to the treatment.
- Liver biochemistry abnormalities: Changes in liver function tests that might indicate potential liver issues.
These safety measures are crucial in determining whether the medication is well-tolerated and safe for long-term use in patients with HIV infections.